FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /

8/19/2022 5:35:09 PM	Chg. +0.050	Volume	Bid5:35:09 PM	Ask8/19/2022	Market Capitalization	Dividend Y.	P/E Ratio
24.620EUR	+0.20%	1.26 mill. Turnover: 30.9 mill.	-Bid Size: -	-Ask Size: -	13.79 bill.EUR	3.73%	7.57

GlobeNewswire 6/11/2021 UPDATE -- Humacyte Expands Strategic Global Partnership with Fresenius Medical Care

GlobeNewswire 6/11/2021 Humacyte Expands Strategic Global Partnership with Fresenius Medical Care

GlobeNewswire 11/11/2019 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...

GlobeNewswire 11/7/2019 eGenesis Announces $100 Million Series B Financing

GlobeNewswire 11/4/2019 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...

GlobeNewswire 10/29/2019 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fresenius Medica...

GlobeNewswire 10/23/2019 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medic...

TeleTrader 8/7/2017 Fresenius Medical buys NxStage for $2 billion

GlobeNewswire 7/19/2017 Akorn Shareholders Vote to Approve Merger Agreement with Fresenius Kabi

GlobeNewswire 6/9/2017 KISSEI TO MARKET AVACOPAN IN JAPAN FOR VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA

GlobeNewswire 4/7/2017 Akorn Confirms Discussions with Fresenius Kabi

GlobeNewswire 1/27/2011 Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab®